Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy

The RIG‐I pathway can be activated by RNA containing 5′ triphosphate, leading to type I interferon release and immune activation. Hence, RIG‐I agonists have been used to induce immune responses against cancer as potential immunotherapy. However, delivery of 5′ triphosphorylated RNA molecules as RIG‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Boya, Nguyen, Trinh Mai, Jayasinghe, Migara Kavishka, Gao, Chang, Pham, Thach Tuan, Vu, Luyen Tien, Yeo, Eric Yew Meng, Yap, Gracemary, Wang, Lingzhi, Goh, Boon Cher, Tam, Wai Leong, Luo, Dahai, Le, Minh TN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013404/
https://www.ncbi.nlm.nih.gov/pubmed/35430766
http://dx.doi.org/10.1002/jev2.12187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013404/
https://www.ncbi.nlm.nih.gov/pubmed/35430766
http://dx.doi.org/10.1002/jev2.12187

Ejemplares similares